Hussein A. Tawbi, MD., Ph.D.

Peer-Reviewed Articles

1. Karz A, Dimitrova M, Kleffman K, Alvarez-Breckenridge C, Atkins MB, Boire A, Bosenberg M, Brastianos P, Cahill DP, Chen Q, Ferguson S, Forsyth P, Glitza Oliva IC, Goldberg SB, Holmen SL, Knisely JPS, Merlino G, Nguyen DX, Pacold ME, Perez-Guijarro E, Smalley KSM, Tawbi HA, Wen PY, Davies MA, Kluger HM, Mehnert JM, Hernando E. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res 35(6):554-572, 2022. e-Pub 2022. PMID: 35912544.
2. Kreidieh FY, Tawbi HA. Current and emerging options for patients with melanoma brain metastases. Clin Adv Hematol Oncol 20(10):619-627, 2022. PMID: 36206074.
3. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1941, 2018. e-Pub 2018. PMID: 30361510.
4. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1942, 2018. e-Pub 2018. PMID: 30361511.
5. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 2018. e-Pub 2018. PMID: 30297909.
6. Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, Butterfield LH, McDermott D, Chen A, Lara PN, Kirkwood JM. NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer 124(22):4332-4341, 2018. e-Pub 2018. PMID: 30303516.
7. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 6(1):103, 2018. e-Pub 2018. PMID: 30305177.
8. Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM. Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol:JCO1800632. e-Pub 2018. PMID: 30359157.
9. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. PMID: 29848573.
10. Keung EZ, Tawbi HA. Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!. Cancer Discov 8(8):914-917, 2018. PMID: 30076141.
11. Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med 379(8):722-730, 2018. PMID: 30134131.
12. Farah M, Nagarajan P, Torres-Cabala CA, Curry JL, Amaria RN, Wargo J, Tawbi H, Ivan D, Prieto VG, Tetzlaff MT, Aung PP. Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. J Cutan Pathol 45(7):545-549, 2018. e-Pub 2018. PMID: 29672900.
13. Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes E, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM. Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila) 11(7):429-438, 2018. e-Pub 2018. PMID: 29691233.
14. Glitza Oliva IC, Schvartsman G, Tawbi H. Advances in the systemic treatment of melanoma brain metastases. Ann Oncol 29(7):1509-1520, 2018. e-Pub 2018. PMID: 29790899.
15. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-193, 2018. e-Pub 2018. PMID: 29361468.
16. Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3(4), 2018. e-Pub 2018. PMID: 29467321.
17. Yam C, Xu X, Davies MA, Gimotty PA, Morrissette JJD, Tetzlaff MT, Wani KM, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas NB, Kudchadkar RR, Pavlick AC, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC. A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24(1):22-32, 2018. e-Pub 2017. PMID: 29051322.
18. Tawbi HA, Bolejack V, Burgess M, Schuetze S. PD-1 inhibition in sarcoma still needs investigation - Authors' reply. Lancet Oncology 19(1):e7, 2018. PMID: 29304367.
19. Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi HA, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3(1):e000283, 2018. e-Pub 2018. PMID: 29387478.
20. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2017. PMID: 29097493.
21. Nguyen NC, Yee MK, Tuchayi AM, Kirkwood JM, Tawbi H, Mountz JM. Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. Front Oncol 8(18):18, 2018. e-Pub 2018. PMID: 29520339.
22. Tawbi HA, Burgess M, Bolejack V. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncology 19(1):E8-E8, 2018.
23. Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi HA, Whitman E, Lee G, Mun Y, Liu S, Hamid O. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res 27(6):585-590, 2017. PMID: 29076950.
24. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncology 18(11):1493-1501, 2017. e-Pub 2017. PMID: 28988646.
25. Davar D, Ding F, Saul M, Sander C, Tarhini AA, Kirkwood JM, Tawbi HA. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. Journal for Immunotherapy of Cancer 5(1):74, 2017. e-Pub 2017. PMID: 28923120.
26. Schvartsman G, Perez K, Sood G, Katkhuda R, Tawbi HA. Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma. Annals of Internal Medicine 167(5):361-362, 2017. e-Pub 2017. PMID: 28761949.
27. Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi HA, Pearce T, Kroll S, Reinke DK, Schöffski P. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol 18(8):1089-1103, 2017. e-Pub 2017. PMID: 28651927.
28. Fang P, Jiang W, Allen P, Glitza I, Guha N, Hwu P, Ghia A, Phan J, Mahajan A, Tawbi HA, Li J. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. Journal of Neuro-Oncology 133(3):595-602, 2017. e-Pub 2017. PMID: 28500560.
29. Schvartsman G, Perez K, Flynn JE, Myers JN, Tawbi HA. Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. Journal for Immunotherapy of Cancer 5:45, 2017. e-Pub 2017. PMID: 28642816.
30. Schuetze SM, Bolejack V, Choy E, Ganjoo KN, Staddon AP, Chow WA, Tawbi HA, Samuels BL, Patel SR, von Mehren M, D'Amato G, Leu KM, Loeb DM, Forscher CA, Milhem MM, Rushing DA, Lucas DR, Chugh R, Reinke DK, Baker LH. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer 123(1):90-97, 2017. e-Pub 2016. PMID: 27696380.
31. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 34(8):786-93, 2016. e-Pub 2015. PMID: 26371143.
32. Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM, Tawbi HA, Rushing DA, Patel SR, Thomas DG, Chugh R, Reinke DK, Baker LH. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer 122(6):868-74, 2016. e-Pub 2015. PMID: 26710211.
33. Beumer JH, Ding F, Tawbi H, Lin Y, Viluh D, Chatterjee I, Rinker M, Chow SL, Ivy SP. Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. J Clin Oncol 34(2):110-6, 2016. e-Pub 2015. PMID: 26392101.
34. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50, 2016. e-Pub 2016. PMID: 27532025.
35. Mesiwala NK, Shemonski N, Sandrian MG, Shelton R, Ishikawa H, Tawbi HA, Schuman JS, Boppart SA, Labriola LT. Retinal imaging with en face and cross-sectional optical coherence tomography delineates outer retinal changes in cancer-associated retinopathy secondary to Merkel cell carcinoma. J Ophthalmic Inflamm Infect 5(1):53, 2015. e-Pub 2015. PMID: 26285790.
36. Burgess M, Gorantla V, Weiss K, Tawbi H. Immunotherapy in Sarcoma: Future Horizons. Curr Oncol Rep 17(11):52, 2015. PMID: 26423769.
37. Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel NH, Wilczynski S, Christensen S, Gandara DR, Chow WA. A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas. Br J Cancer 112(10):1644-51, 2015. e-Pub 2015. PMID: 25897676.
38. Shou Y, Robinson DM, Amakye DD, Rose KL, Cho YJ, Ligon KL, Sharp T, Haider AS, Bandaru R, Ando Y, Geoerger B, Doz F, Ashley DM, Hargrave DR, Casanova M, Tawbi HA, Rodon J, Thomas AL, Mita AC, MacDonald TJ, Kieran MW. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res 21(3):585-93, 2015. e-Pub 2014. PMID: 25473003.
39. Villaruz LC, Huang G, Romkes M, Kirkwood JM, Buch SC, Nukui T, Flaherty KT, Lee SJ, Wilson MA, Nathanson KL, Benos PV, Tawbi HA. MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clin Epigenetics 7(1):58, 2015. e-Pub 2015. PMID: 26052356.
40. Bakkenist CJ, Czambel RK, Hershberger PA, Tawbi H, Beumer JH, Schmitz JC. A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells. Oncoscience 2(5):542-54, 2015. e-Pub 2015. PMID: 26097887.
41. Lee DH, Zhang Y, Kassam AB, Park MJ, Gardner P, Prevedello D, Henry S, Horbinski C, Beumer JH, Tawbi H, Williams BJ, Shaffrey ME, Egorin MJ, Abounader R, Park DM. Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma. PLoS One 10(8):e0134426, 2015. e-Pub 2015. PMID: 26247786.
42. Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 20(7):1900-9, 2014. e-Pub 2014. PMID: 24523439.
43. Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8 T cells induced by melanoma vaccines. Cancer Res 74(4):1045-55, 2014. e-Pub 2013. PMID: 24343228.
44. Tawbi H. Selective BRAF inhibitors make inroads in mutated metastatic melanoma. J Community Support Oncol 12(2):46-7, 2014. PMID: 24971403.
45. Tawbi H, Christner SM, Lin Y, Johnson M, Mowrey ET, Cherrin C, Chu E, Lee JJ, Puhalla S, Stoller R, Appleman LR, Miller BM, Beumer JH. Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. Cancer Chemother Pharmacol 73(1):207-11, 2014. e-Pub 2013. PMID: 24170263.
46. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, Rao UN, Kirkwood JM. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 9(2):e87705, 2014. e-Pub 2014. PMID: 24498358.
47. Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 3(1):e27589, 2014. e-Pub 2014. PMID: 24734217.
48. Tawbi HA, Tran AL, Christner SM, Lin Y, Johnson M, Mowrey E, Appleman LR, Stoller R, Miller BM, Egorin MJ, Beumer JH. Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. Cancer Chemother Pharmacol 72(5):1143-7, 2013. e-Pub 2013. PMID: 24036846.
49. Kiesel BF, Parise RA, Tjørnelund J, Christensen MK, Loza E, Tawbi H, Chu E, Kummar S, Beumer JH. LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma. J Pharm Biomed Anal 81-82:89-98, 2013. e-Pub 2013. PMID: 23644904.
50. Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Buch SC, Egorin MJ, Lin Y, Christner S, Kirkwood JM. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol 24(4):1112-9, 2013. e-Pub 2012. PMID: 23172636.
51. Kirkwood JM, Tarhini A, Sparano JA, Patel P, Schiller JH, Vergo MT, Benson Iii AB, Tawbi H. Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. Cancer Treat Rev 39(1):27-43, 2013. e-Pub 2012. PMID: 22520262.
52. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087-95, 2012. e-Pub 2012. PMID: 23051966.
53. Shaw PH, Boyiadzis M, Tawbi H, Welsh A, Kemerer A, Davidson NE, Ritchey AK. Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions. Cancer 118(14):3614-7, 2012. e-Pub 2011. PMID: 22213134.
54. Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 30(3):322-8, 2012. e-Pub 2011. PMID: 22184371.
55. Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care 16(4):231, 2012. e-Pub 2012. PMID: 22967460.
56. Tawbi HA, Villaruz L, Tarhini A, Moschos S, Sulecki M, Viverette F, Shipe-Spotloe J, Radkowski R, Kirkwood JM. Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer 105(6):773-7, 2011. e-Pub 2011. PMID: 21811257.
57. Beumer JH, Tawbi H. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol 5(3):196-208, 2010. PMID: 20406169.
58. Tawbi H, Thomas D, Lucas DR, Biermann JS, Schuetze SM, Hart AL, Chugh R, Baker LH. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist 13(4):459-66, 2008. PMID: 18448562.
59. Tarhini AA, Kirkwood JM, Tawbi H, Gooding WE, Islam MF, Agarwala SS. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer 112(5):1131-8, 2008. PMID: 18286511.
60. Arayssi TK, Tawbi HA, Usta IM, Hourani MH. Calcitonin in the Treatment of Transient Osteoporosis of the Hip. Semin Arthritis Rheum 32(6):388-97, 2003. PMID: 12833247.

Invited Articles

1. Burgess M, Tawbi H. Immunotherapeutic approaches to sarcoma. Curr Treat Options Oncol 16(6):26, 2015. PMID: 25975445.
2. Gorantla V, Kirkwood JM, Tawbi HA. Melanoma brain metastases: an unmet challenge in the era of active therapy. Curr Oncol Rep 15(5):483-91, 2013. PMID: 23954973.
3. Tran A, Tawbi HA. A potential role for nilotinib in KIT-mutated melanoma. Expert Opin Investig Drugs 21(6):861-9, 2012. e-Pub 2012. PMID: 22500535.
4. Tawbi HA, Buch SC. Chemotherapy resistance abrogation in metastatic melanoma. Clin Adv Hematol Oncol 8(4):259-66, 2010. PMID: 20505649.
5. Tawbi HA, Nimmagadda N. Targeted therapy in melanoma. Biologics 3:475-84, 2009. e-Pub 2009. PMID: 20054438.
6. Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol 34(6):532-45, 2007. PMID: 18083377.
7. Chugh R, Tawbi HA, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: The Nonsarcoma Primary Bone Tumor. The Oncologist 12(11):1344-50, 2007. PMID: 18055855.

Editorials

1. Tawbi HA. Combination therapies for treating metastatic melanoma. Clin Adv Hematol Oncol 13(4):211-4, 2015. PMID: 26352577.
2. Tawbi HA. Matching wits with melanoma brain metastases: from biology to therapeutics. Clin Cancer Res 20(21):5346-8, 2014. PMID: 25135484.
3. Tawbi HA, Kirkwood JM. Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect. Nat Rev Clin Oncol 9(9):496-7, 2012. PMID: 22889973.
4. Kirkwood JM, Tawbi HA, Tarhini AA, Moschos SJ. Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?. Nat Clin Pract Oncol 6(2):70-1, 2009. PMID: 19092800.

Abstracts

1. Diab A, Haymaker C, Uemura M, Murthy R, James M, Geib J, Cornfeld M, Swann S, Yee C, Wargo J, Amaria R, Patel S, Tawbi H, Glitza I, Woodman S, Hwu WJ, Davies MA, Overwijk W, Bernatchez C, Hwu P. A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma. 42nd European Society for Medical Oncology Congress (ESMO) 28, 2017.
2. Gasal E, Fernandez AMA, Ascierto PA, Atkinson V, Dummer R, Flaherty KT, Grob JJ, Hansson J, Hassel J, Larkin J, Lebbe C, Long GV, Lorigan P, Miller W, Nathan P, Ribas A, Robert C, Schadendorf D, Tawbi, HT, Upalawanna A. A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i). Annals of Oncology 28, 2017.
3. Schvartsman G, Ma J, Bassett RL, Haydu LE, Amaria RN, Hwu P, Hwu WJ, Diab A, Patel SP, Davies MA, Tawbi HA, Glita IC. Incidence, patterns of progression and outcomes of melanoma brain metastasis (MBM) during programmed-death 1 inhibitor (PD1i) therapy. Journal of Clinical Oncology 35, 2017.
4. Chen WS, Cameron M, Spencer C, Tawbi HA, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, Davies MA, Gershenwald JE, Sharma P, Allison JP, Futreal A, Wargo JA. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). Journal of Clinical Oncology 35, 2017.
5. Burgess MA, Bolejack V, Van Tine BA, Schuetze S, Hu J, D'Angelo SP, Attia S, Priebat DA, Okuno SH, Riedel RF, Davis LE, Mowa S, Reed DR, Butterfield LH, Roszik J, Reinke DK, Baker LH, Maki RG, Patel S, Tawbi HA. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. Journal of Clinical Oncology 35, 2017.
6. Keung E, Burton EM, Amaria RN, Glitza IC, Patel SP, Diab A, Yee C, Wong MK, Hwu WJ, Hwu P, Woodman SE, Tetzlaff MT, Milton D, Perez K, Davies MA, Rai K, Wargo JA, Tawbi HA. A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients with metastatic melanoma (MM). Journal of Clinical Oncology 35, 2017.
7. McKean MA, Haydu LE, Ma JS, Bassett RL, Hwu WJ, Patel SP, Diab A, Glitza IC, Tawbi HA, Wong MK, McQuade JL, Hwu P, Davies MA, Amaria RN,. Prognostic factors for overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with immune checkpoint inhibitors: A single institution study of 696 pts. Journal of Clinical Oncology 35, 2017.
8. Patel SP, Glitza IC, Diab A, Amaria RN, Davies MA, Hwu P, Tawbi HA, Hwu WJ. The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with uveal melanoma (UM). Journal of Clinical Oncology 35, 2017.
9. Tawbi HA, Forsyth PA, Algazi AP, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Gonzalez R, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini AA, Jiang J, Avila A, Demelo S, Margolin KA. Efficacy of safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. Journal of Clinical Oncology 35, 2017.
10. Tawbi HA, Burgess MA, Crowley J, Van Tine BA, Hu J, Schuetze Scott, D'Angelo SP, Attia S, Priebat DA, Okuno SH, Riedel RF, Davis LE, Movva S, Reed DR, Baker LH, Reinke DK, Maki RG, Patel S.. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARCO28-A multicenter phase II study. ASCO Annual Meeting 2016, 2016.
11. Barcena E, Trinh VA, McIntyre SE, Simien R, Cain S, Diab A, Amaria RN, Patel SP, Glitza IC, Tawbi HA, Davies MA, Hwu WJ. Responses in patients with BRAF V600-mutant metastatic melanoma receiving anti-PD1/PDL1 therapy alone or combined with BRAF inhibitors. ASCO Annual Meeting 2016, 2016.
12. Shaw AC, Trinh VA, Bassett RL, Glitza IC, Diab A, Amaria RN, Tawbi HAH, Davies M, Hwu WJ, Hwu P, Patel SP. Retrospective analysis of safety and efficacy of ipilimumab in elderly patients with advanced melanoma. J Clin Oncol 34, 2016.
13. Burgess MA, Nathenson M, Kasi PM, Khalil L, Ross M, Tawbi HAH. A case series of sarcoma brain metastases (SBM): A single-institution experience. J Clin Oncol 34, 2016.
14. Rohlfs M, Bassett RL, Lacey C, McQuail N, Mehta U, John I, Simien R, Tupue S, Dett TK, Glitza IC, Diab A, Amaria RN, Tawbi HA, Davies M, Hwu WJ, Hwu P, Patel SP. BRAF with or without MEK inhibition plus PD-1 checkpoint blocade for the treatment of metastatic melanoma. ASCO Annual Meeting 2016, 2016.
15. Tarhini AA, Rahman Z, Pryanka V, Tawbi HA, Gnan A, McFadden A, Rose A, Pruckner C, Wilson M, Pingpank JF, Hotzman MP, Ferris RL, Rao UNM, Kirkwood JM. Neoadjuvant combination immunotherapy with ipilimumab (3 mg/kg or 10mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma. J Clin Oncol 34, 2016.
16. Amaria RN, Haymaker CL, Bernatchez C, Forget MA, Patel V, Hwu WJ, Davies MA, Patel SP, Diab A, Glitza IC, Tawbi HAH, Woodman SE, Wargo JE, Ross MI, Lee JE, Gershenwald JE, Cormier JN, Royal RE, Lucci A, HWU P. A phase I/ii study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CSCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM). j Clin Oncol 34, 2016.
17. Krikwood JM, Sing S, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UNM, Sander C, Tarhini AA, Tawbi HA, Ferris L, Wilson M, Petrany M, Rose A, Fahey JW, Leachman SA, Cassidy P, Butterfield LH, Zarour HM. Does-response evaluation of brocolli sprout extract sulforaphane (BSE-SFN) in melanoma patients (Pts) with atypical/dysplatic nevi (A/DN). J Clin Oncol, 2016.
18. Davar D, Wang H, Chauvin JM, Sun Z, Pagliano O, Rose A, Muniz C, Sander C, Fourcade JJ, Rao UNM, Ibrahim N, Ebbighaus S, Tawbi HA, Tarhini AA, Kirkwood JM, Zarour HM, Russo G. Phase 1B study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL). ASCO Annual Meeting 2016, 2016.
19. Pahuja S, Beumer JH, Appleman LJ, Tawbi HA, Stoller RG, Lee JJ, Lin Y, Ding F, Yu J, Belani CP, Chen AP, Giranda VL, Shepherd SP, Chu E, Puhalla S. A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC). J Clin Oncol 33, 2015.
20. Zarour HM, Tawbi HA, Tarhini AA, Wang H, Sander C, Rose A, Fourcade JJ, Chauvin JM, Sun Z, Paliano O, Kirkwood JM. Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma. ASCO 2015 Annual Meeting, 2015.
21. Yee MK, Lin Y, Gorantla VC, Butterfield LH, Kluger HM, Chapman PB, Gangadhar TC, Milhem MM, Pavlic AC, Amaravadi RK, Schuter LM, Tarhini AA, Kirkwood JM, Tawbi HA. Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metasteses (coBRIM-B). J Clin Oncol(33), 2015.
22. Margolin KA,Tawbi HA, Enstoff MS, Hodi FS, McDermott DF, Edward R, Avila A, Atkins MB. A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain. J Clin Oncol(33), 2015.
23. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze S, Staddon AP, Milhem MM, Elias AD, Ganjoo KN, Tawbi HA, Van Tine BA, Spira AL, Dean AP, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel S. A randomized phase III study of travectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomysarcoma (LMS). J Clin Oncol(33), 2015.
24. Burgess MA, Crowley J, Reinke DK, Riedel RF, George S, Movva S, Van Tine BA, Davis LE, Schuetze S, Hu J, Attia S, Priebat DA, Reed DR, D'Angelo SP, Okuno SH, Maki RG, Patel S, Baker LH, Tawbi HA. SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (pts) with advanced sarcomas. J Clin Oncol(33), 2015.
25. Tawbi HA, Chu E, Lin Y, Hyman D, Goel S, Rudek M, Dowlati A, LoRusso P, Mulkerin D, Chew H, Chung V, Harvey D, Shapiro G, Belani C, Applemenn L, Puhalla S, Stoller R, Lee J, Pollice L, Ivy P, Beumer JH. Early phase I study of PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction-a study of the NCI-organ dysfunction working group (OGD). Presented at the 50th American Society fo Clinical Oncology Annual Meeting, 2014.
26. Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel N, Wilczynski S, Christensen S, Gandara DR, Chow WA. NCI:8412 A randomized phase II trial of AZD6244 alone and AZD6244 plus temsirolimus for soft-tissue sarcomas. Presented at the 50th American Society of Clinical Oncology Annual Meeting, 2014.
27. Tarhini AA, Lin Y, Lin H, LaFrambroise WA, Rao UNM, Tawbi HA, Ashraf M, Pingpank JF, Holtzman MP, Sciulli C, Sander C, Kirkwood JM. A unique gene expression signature in tumor positive or negative sentinel lymph nodes in patients with melanoma. Journal of Clinical Oncology, Presented at the 50th American Society of Clinical Oncology Annual Meeting 32(5S), 2014.
28. Ashraf M, Kirkwood JM, Emsloft MS, Tawbi HA, Frankel PH, Ruel N, Kendra KL, Olencki T, Khushalani NI, Logan TF, Marolin Ka, Chen AP, Tarhini AA. NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma - efficacy and biomarker study. Presented at the 50th American Society of Clinical Oncology Annual Meeting 32(5s), 2014.
29. Davies MA, Tawbi H, Ouellet D, Lazar AJF, Weinberg JS, Butterfield LH, Hamilton RL, Armankulor N, Engh JA, Shivalingham B, Kefford R, Scoyler RA, Mahmood S, Richards-Peterson LE, Swann S, Arbushities MC, Long GV, Kirkwood JM. Pharmacokinetic and pharmacodynamics analysis of preoperative therapy with dabrafenib alone and in combination with trametinic in patients wish BRAF mutation-posisitve melanoma with metastases to the brain (BRV116521). Presented at the 50th American Society of Clinical Oncology Annual Meeting 32(5s), 2014.
30. Puhalla S, Beumer JH, Pahuja S, Appleman LJ, Tawbi HA, Stoller RG, Lee JJ, Lin Y, Kiesel B, Yu J, Tan AR, Belani CP, Chew HK, Garcia AA, Morgan R, Giranda VL, Shepherd SP, Chen AP, Chu E. Final results of a phase 1 study of single-agent velipariv (V) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinium-refractory ovarian, or basal-like breast cancer (BRCA-wt). J Clin Oncol 32(5s), 2014.
31. Carvajal RD, Agulink M, Ryan CW, Mihem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi HA, Elias AD, Read WL, Budd GT, Himan J, Weiden P, Bennett CM, Livingston PO, Hansen D, Maki RG, Schwartz GK, Chugh R. Tirvalent gangsliode vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial. J Clin Oncol 32(5s), 2014.
32. Davar D, Saul M, Trent K, Holtzman MP, Edington H, Tawbi HA, Tarhini AA, Kirkwood JM. Prognostic significance of sentinel lymph node biopsies (SLNB) in melanoma. J Clin Oncol 32, 2014.
33. Villaruz LC, Huang G, Romkes M, Kirkwood JM, Buch SC, Nukui T, Flaherty K, Lee SJ, Lee A, Pandit K, Abecassis I, Nathanson KL, Benos PV, Tawbi HA. microRNA (miRNA) expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy (CP) in metastatic melanoma (MM) treated on the intergroup trial E2603. J Clin Oncol 32(5s), 2014.
34. Davar D, Tarhini AA, Tawbi HA, Ferrone S, Zarour HM, Kirkwood JM. Dose seeking and efficacy study of combination BRAFi and high-dose IFN(HDI) therapy for therapy of advanced melanoma. J Clin Oncol 32(5s), 2014.
35. Gangadhar TC, Xu X, Karakousis G, Amaravadi RK, Haas N, Kudchadkar R, Pavlick A, Sosman JA, Tawbi HA, Walker L, Schuchter LM. Multi-institution phase I study of BRAF (vemurafenib) and P13K inhibition (PX-866) in advanced BRAF mutant solid tumors in melanoma. Society of Melanoma Research, Oral Presentation, 2013.
36. Tarhini AA, LaFramboise WA, Rao UNM, Edington H, Pingpank JF, Hotzman MP, Tawbi HA, Geskin A, Rose A, Milburn C, Merriman M, Sander C, Sciulli C, Lin Y, Kirwood JM. Differential genomic profiles of tumor-involved and tumor-free sentinel lymph nodes in patients with melanoma. ASCO 2013 Annual Meeting, 2013.
37. Tarhini AA, Edington H, Butterfield LH, Tawbi H, Moschos SJ, Shuai Y, Lin Y, Horak M, Sarkisian S, Shipe-Spotloe J, Milburn C, Sander C, Johnson JT, Kirkwood JM. Neoadjuvant ipilimumab in locally/regionally advanced in melanoma: clinical outcome and immune monitoring. ASCO 2012 Annual Meeting, 2012.
38. Carvajal RD, Chugh R, Milhem MM, Ryan CW, George S, Chmielowski B, Agulnik M, Rodler ET, Elias AD, Budd GT, Tawbi H, Movva S, Van Tine BA, Dickinson MA, Hensley ML, Keohan MIL, Tap WD, Bennett CM, Maki RG, Schwartz GK. Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastasectomy. ASCO 2012 Annual Meeting, 2012.
39. Appleman LJ, Beumer JH, Jian Y, Puhalla S, Lin Y, Owonikoko TK, Harvey RD, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Kiesel B, Chu E, Shepherd SP, Giranda VL, Chen AP, Belani CP, Ramalingam SS. A phase I study of veliparib (ABT-888) in combinatin with carboplatin and paclitaxel in advanced solid malignancies. ASCO 2012 Annual Meeting, 2012.
40. Rios-Perez JA, Beumer JH, Appleman LJ,Tawbi HA, Chu E, Stoller RG, Belani CP, Jian Y, Sobol RW, Shepherd SP, Giranda VL, Chen AP, Huggins-Puhalla SL. ABT-888 (veliparib) in combination with weekly carboplatin and paclitaxel in advanced solid tumors. ASCO 2012 Annual Meeting, 2012.
41. Lobur D, Davar D, Singh S, Beumer JH, Edington H, Tarhini AA, Tawbi H, Zarour HM, Talalay P, Kirkwood JM. Pilot evaluation of sulforaphane in melanoma patients with multiple atypical nevi: Tissue STAT1 and STAT3 as risk markers. ASCO 2012 Annual Meeting, 2012.
42. Krauze MT, Hamilton RH, Romkes M, Boroluzzi S, Harasymczuk M, Reinhard T, Junecko BF, Nukui T, Konstantinopoulos P, Becker D, Kondziolka D, Tarhini AA, Whiteside T, Mintz AH, Tawbi H, Ferrone S, Kirkwood JM, Moschos SJ. Association of high T-cell immune infiltrate and low hemorrhage in melanoma brain metastases (MBMs) with prolonged survival. ASCO 2012 Annual Meeting, 2012.
43. Huggins-Puhalla SL, Beumer JH, Appleman LJ, Tawbi HA, Stoller RG, Lin Y, Kiesel B, Tan AR, Gibbon D, Jian Y, Garcia A, Chew HK, Morgan R, Shepherd SP, Giranda VL, Chen AP, Belani CP, Chu E. A phase I study of chornically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt). ASCO 2012 Annual Meeting, 2012.
44. Tawbi HA, Rodon Anhert J, Dummer R, Thomas AL, Granvil C, Shou Y, Dey J, Mita MM, Amakye DD, Mita AC. Phase I study of LDE225 in advanced solid tumors: updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation. ASCO Annual Meeting, 2011.
45. Beumer JH, Tawbi HA, Tarhini AA, Moschos SJ, Egorin MJ, Buch SC, Lin Y, Kirkwood JM. Final results of phase I/II study of decitabine (DAC) combined with temozolomide (TMZ) in metastatic melanoma (MM). ASCO Annual Meeting, 2011.
46. Tarhini AA, Edington H, Butterfield LH, Sinha M, Moschos SJ, Tawbi H, Shuai Y, Shipe-Spotloe J, Simonetta M, Milburn, Horak M, Sander C, Kirkwood JM. Neoadjuvant ipilimumab in patients with stage IIIb. ASCO 2011 Annual Meeting, 2011.
47. Schuetze SM, Wathen K, Choy E, Ganjoo KN, Chow WA, Staddon AP, Samuels BL, Tawbi H, Patel S, Demetri G, Baker LH. SARC009: Results of a SARC Phase II trial of dasatinib in alveolar soft part sarcoma, chondrosarcoma, chordoma, epitheliod sarcoma and hemangiopercytoma. CTOS Annual Meeting, 2010.
48. Rodon J, Baselga J, Tawbi HA, Shou Y, Feng W, Dummer R, Mahalingam D, Thomas A, Amakye D, Mita AC. Phase I safety and pharmacologic results in patients with advanced solid tumors. ESMO Congress 2010, 2010.
49. Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Egorin MJ, Buch S, Lin YC, Lin Y, Kirkwood JM. Phase I/II study of the combination of decitabine (DAC) and temozolomide (TMZ) in patients (pts) with metastatic melanoma (MM). ASCO 2010 Annual Meeting, 2010.
50. Rodon Ahnert J, Baselga J, Tawbi HA, Shou Y, Granvil C, Dey J, Mita MM, Thomas AL, Amakye DD, Mita AC. A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. ASCO 2010 Annual Meeting, 2010.
51. Tarhini AA, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM. Phase II evaluation of tremelimuma (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma. ASCO 2010 Annual Meeting, 2010.
52. Tawbi HA, Lin YC, Villaruz L, Egorin MJ, Beumer JH, Buch S, Kirkwood JM, Soboll RW. Enhanced cytotoxicity of carboplatin and paclitaxel (CP) by vorinostat (SAHA), a histone deacetylase (HDAC) inhibitor, in melanoma cell lines. AACR 101ST 2010 Annual Meeting, 2010.
53. Tawbi HA, Buch S, Pancoska P, Lin Y, Saul M, Romkes M, Sobol R, Kirkwood J. Prediction of response to alkylator-based chemothrapy in metastatic melanoma (MM) using gene expression and promoter methylation signatures. ASCO 2009 Annual Meeting, Oral Presentation, 2009.
54. Tarhini A, Christensen S, Frankel P, Margolin K, Ruel C, Tawbi HA, Shipe-Spotloe J, DeMark M, Kirkwood JM. Phase II study of afilibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or cular origin. ASCO 2009 Annual Meeting, 2009.
55. Tawbi HA, Papachristou D, Buch S, Michalopoulos G, Rao U. Ewing's sarcoma (EWS) and synovial sarcoma (SS) have distinct microRNA expression profiles. AACR 2009 Annual Meeting, 2009.
56. Tawbi HA, Tarhini A, Moschos S, Sulecki M, Viverette F, Radkowski R, Shipe-Spotloe J, Kunkel C, Rae M, Kirkwood J. Phase I trial of lomeguatrib (Patrin, PN) combined with dacarbazine (DTIC) for treatment of patients with melanoma and other solid tumors: initial results. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part 1, 24(18S (June 20 Supplement)), 2006.
57. Sobol RW, Tawbi HA, Jukic DM, Mule K, Mascari R, Kirkwood JM. Mismatch repair (MMR) and base excision repair (BER) protein expression correlates with clinical response to darbazine (DTIC)/Temozolomide (TMZ) therapy of patients with metastatic melanoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part 1, Vol 24(18S, June 20 Supplement), 2006.
58. Ng YH, Tawbi HA, Granieri R.. A sore throat gone awry. Society of General Internal Medicine under the category of "Unknown Clinical Vignette", 2005.

Book Chapters

1. Tawbi H, Kirkwood JM. Riegel, Cancer of the Skin. In: Imaging of the Melanoma Patient. Second, 2011.

Letters to the Editor

1. Beumer JH,Tawbi HA, Ivy SP. Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al. J Clin Oncol 34: 2430-1, 2016.